Table 2.
Summary of results of salvage treatment (n = 45)
| Follow-up (months), mean (SD) | 42.7 | (±20.8) |
|---|---|---|
| Median PSA-nadir after salvage ePLND, ng/ml (SD) | 4.4 | ± 1.5 |
| N-stage after salvage ePLND | ||
| N0 (%) | 19 | (42.2 %) |
| N1 (%) | 26 | (58.7 %) |
| No. of LNs removed (range) | 971 | (4–76) |
| Mean no. of LNs removed per patient (SD) | 21.6 | (±9) |
| No. of positive LNs (range) | 183 | (1–42) |
| No. of positive LNs per patient (range) | 4,1 | (1–42) |
| No. of deaths (%) | 7 | (15.6 %) |
| Time to death (months), mean (range) | 48.8 | 5–105 |
| BR after salvage ePLND n (% patients) | 31 | (68.9 %) |
| BCRF immediately after salvage ePLND (complete BR) n (% patients) | 22 | (48.9 %) |
| BCRF during follow-up n (% patients) | 33 | (73.3 %) |
| Mean BCRF duration (months) (SD) | 31.4 | (±19.7) |
| ADT before salvage ePLND No. (%) patients |
36 | (80.0 %) |
| ADT after salvage ePLND No. (%) patients |
40 | (88.9 %) |
| Bone metastases in follow-up after salvage ePLND No. (%) patients |
10 | (22.2 %) |